Essex Management LLC

Essex Management LLC, a privately held biomedical informatics and life sciences IT consulting firm based in Rockville, Maryland, operates as a prime contractor (95% of recent awards) delivering specialized health IT services, clinical trial informatics platforms, cancer surveillance systems, and biomedical data infrastructure to the National Institutes of Health on a full-and-open basis with no set-aside designations. Essex is a subsidiary of The Emmes Company, LLC and competes without SBA certifications, positioning itself as a specialized federal contractor rather than a small-business set-aside vendor.

Customer concentration at Essex is extreme and structural. The National Cancer Institute accounts for 14 awards and $1.12 billion of the $1.13 billion combined potential value across the entire prime portfolio — 99% of dollars. The remaining six customer agencies (NIH Office of the Director, NIH general, NIH NITAAC, NIH NIDDK, NIH NICHD, and GSA) together represent less than 1% of potential value and serve as minor secondary outlets. This concentration reflects Essex's positioning as an embedded NCI informatics contractor with deep institutional knowledge of the agency's cancer surveillance, clinical trials, and health data systems.

Essex's capability portfolio centers on time-and-materials delivery of cancer surveillance registry support, clinical trial reporting and operations platforms, biomedical data system development, and health informatics analytics. Recent representative work includes a $28.3 million delivery order (ultimate completion August 31, 2031) for Clinical Trials Reporting Office and Support Services under the BITSDIS IDIQ, a $20.3 million order for Connect for Cancer Prevention Data System support (through May 14, 2031), a $15.4 million order for Biomedical Data and Informatics Systems Support (through September 21, 2031), and a $15.1 million order for Clinical Reporting and Research Informatics (through August 31, 2027). A $5.0 million order issued in September 2023 supports the National Childhood Cancer Registry. SCI-reported invoicing across federal service contracts ran $97 million from FY2022 through FY2025 (roughly $22–26 million annually), with a government-paid blended rate spectrum spanning $93.13/hr at the tenth percentile to $173.88/hr at the ninety-eth percentile, reflecting a mix of technical support roles and senior informatics and project-management positions. GSA Schedule labor categories range from IT Technical Administrator roles at $62.40/hr through Specialized Principal IT Subject Matter Expert positions at $325.08/hr, with education requirements spanning associate through doctorate degrees and no security-clearance requirements.

Essex holds three primary parent vehicle positions. The Biomedical Information Technology, Software Development, and Informatics Support (BITSDIS) IDIQ generated 11 task orders totaling $181.1 million in combined potential value and serves as the primary delivery vehicle for Essex's NCI work. Essex also holds a $548 million Cancer Trials Support Unit (CTSU) IDIQ through July 31, 2027, under which it performs operational, regulatory, and IT support to multi-institutional cancer trials led by NCI-supported clinical trial organizations; task areas three through six are unrestricted for all contractors, while task area two is single-awarded. A third vehicle is a blanket purchase agreement with NIDDK (the National Institute of Diabetes and Digestive and Kidney Diseases) on behalf of NCI running through November 9, 2027, with no stated ceiling, carrying delivery orders on time-and-materials and labor-hours bases. Essex also holds positions on GSA Multiple Award Schedule and Federal Supply Schedule GS35F0489X vehicles, generating $51.4 million and $1.9 million in combined potential value respectively, though these represent minor secondary outlets relative to the NCI-anchored IDIQs.

Recent activity shows concentration risk. Awards per year declined from four in 2021 to one in 2024, then rebounded to five in 2026 (three issued in September 2026 alone). The recompete cliff is modest: only three awards reach ultimate completion within the next twenty-four months, totaling $18.9 million in potential value. However, the substantial multi-year delivery orders executed in September 2026 (the $28.3 million CTRO-SS order through August 2031, the $20.3 million C4CPDS order through May 2031, and the $15.4 million BDISS order through September 2031) represent a significant expansion of Essex's long-term NCI footprint and materially extend the contract tail beyond near-term recompete exposure.

Essex operates as a light prime, not a subcontractor distributor. Across SCI-reportable prime contracts, subcontractors supplied 17% of total contractor hours on average, with 50 named subcontractors involved across the portfolio. The vendor employs roughly 90–110 FTEs on federal service contracts annually (FY2022 through FY2025), with FY2024 marking a peak of 105 FTEs before moderating to 97.7 in FY2025. Essex subcontracts minimally as a partner to other primes; a single named sub-award appears in the source — senior project management support to Panamerica Computers, Inc. on a SERONET real-world data infrastructure and COVID-19 serology project for NCI.

Combined potential value across the prime footprint totals $1.13 billion against $175.6 million obligated to date (15% of potential), reflecting the weighted presence of five large multi-year delivery orders placed in 2026 that carry ceilings extending through 2031. Growth in the pipeline is evident in the September 2026 ordering activity and the shift toward larger, longer-duration task orders under BITSDIS and CTSU, but execution and recompete risk remain concentrated with a single customer whose procurement policies, budget cycles, and program priorities determine Essex's federal revenue trajectory.